Company Profile

Idun Pharmaceuticals (AKA: IDUN)
Profile last edited on: 12/16/2009      CAGE:       UEI:

Business Identifier: Therapies to control apoptosis, a process of cell death
Year Founded
1993
First Award
1999
Latest Award
1999
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9380 Judicial Drive
San Diego, CA 92121
   (858) 623-1330
   N/A
   N/A
Location: Single
Congr. District: 52
County: San Diego

Public Profile

In February 2005, Idun was acquired by Pfizer. Idun Pharmaceuticals creates innovative human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. In addition to its research and development of small molecule activators of apoptosis for cancer therapy, Idun's drug discovery programs are directed to finding small molecule inhibitors of apoptosis for applications in central nervous system disorders, cardiovascular disease, inflammation, and acute organ damage. Idun Pharmaceuticals is a developer of human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. Management believe that control of the cell death process will have utility in treating cancer, neurodegenerative diseases, ischemic disorders, and cardiovascular disease.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
75-99
Revenue Range
7.5M-10M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
50-74

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1999 1 NIH $99,401
Project Title: Granulocyte Preservation Using Apoptosis Inhibitors

Key People / Management

  Steven J Mento -- President

  John F Burrows

  Charles J Cashion -- CFO

Company News

There are no news available.